5 Papers
R. Wu is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
Shao-Hua Lu,J. Zhou,Hong Jian,Y. Cheng,Jianmin Fang,G. Chen,Z. Zhang,D Lv,L. Jiang,R. Wu,X. Jin,X. Zhang,J Zhang,Guilan Sun,D. Huang,Jiuwei Cui,R.P. Guo,Lihui Ding +17 more
TL;DR: Befotertinib (D-0316) exhibited encouraging antitumor activity in a pivotal phase II study (NCT03861156) in EGFR T790M mutation-positive patients (pts) as mentioned in this paper .
2
EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Shao-Hua Lu,Yan Zhang,G. Zhang,J. Zhou,Shundong Cang,Y. Cheng,G.Y. Wu,Pengfei Cao,Dashuai Lv,Hong Jian,C. Chen,X. Jin,P. Tian,K. Wang,G. Jiang,G.W. Chen,Qi Chen,H. J. Zhao,C. Ding,R.P. Guo,G. Sun,B. Wang,Z. Liu,J. Fang,J Yang,Wu Zhuang,Y. Liu,J.P. Zhang,J Chen,Q. Yu,M. Zhao,Jiuwei Cui,D. Li,Tienan Yi,Z. R. Yu,Y. Yang,X Zhi,Y. Huang,R. Wu,Li Chen,A. F. Zang,L. Cao,Q. Li,X Li,Yang Song,D. Wang,S. Zhang +46 more
TL;DR: Befotertinib (D-0316) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) as mentioned in this paper .
1
313P A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Y Yu,W. J. Dong,Yi Shi,R. Wu,Q. Yu,Feng Ye,C.S. Zhou,X. Dong,X Z Liu,Z. Li,H. Shen,D. Wu,Z. Xu,J Wu,Ning Xu,Y Q Qin,J Li,Shao-Hua Lu +17 more
TL;DR: SCC244, a highly selective and potent oral MET TKI, demonstrated high efficacy and acceptable safety profile in NSCLC patients with MET exon 14 skipping mutation as discussed by the authors .
1
Verification of cell cycle-associated cyclin-dependent kinases facilitated prostate cancer progression by integrated bioinformatic analysis and experimental validation
Yean Huang,Shuo Lu,Yi Chen,Yunhao Qing,R. Wu,Tanbin Ma,Zixiao Zhang,Yu Wang,Kezhong Li +8 more
TL;DR: In this article , the authors examined the effect of CDK1/3/4/5/6/16 on the progression of prostate cancer and identified the gene functions of ccCDK in PCa.
LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
C. Zhou,Z. Wang,Yihua Sun,L. Cao,Zhiyong Ma,R. Wu,Yang Yu,W. Yao,J. Chang,Jun Chen,Wu Zhuang,Jiuwei Cui,Xi Chen,Yilu Lu,H. Shen,Peng Li,J. Wang,B. Sun,D. Lu,Jin-Ji Yang +19 more